MedTech Acquisition Corporation (MTAC) Adjourns Completion Vote
by Marlena Haddad on 2023-08-02 at 5:26pm

MedTech Acquisition Corporation (Nasdaq: MTAC) announced this afternoon that it convened and then adjourned its completion vote for its business combination with drug developer TriSalus Life Sciences.

The special meeting, initially planned for today, has been rescheduled to 11:00 a.m. ET on August 8. In connection with the adjournment, MedTech has extended the deadline for stockholders to submit their shares for redemption to 5:00 p.m. ET on August 4.

Prior to today’s meeting, MTAC filed an 8-K regarding the written response received by TriSalus from the FDA in reference to a meeting request for TriSalus’ PERIO-01 clinical program. The FDA acknowledged that early data from the program showed that TriSalus’ pressure-enabled drug delivery (PEDD) method had a tolerable safety profile and has requested further exploration of the dose before proceeding with a registrational trial.

TriSalus plans to have Phase 1 efficacy data for multiple SD-101 doses by the second half of 2023. As a result of the FDA’s responses, TriSalus expects a potential new drug application submission for SD-101 in uveal melanoma with liver metastases to likely occur beyond 2025, pending Phase 2 data.

MedTech initially announced its $234 million combination with TriSalus Life Sciences in November. Within the past few months, the parties agreed to drop the deal’s minimum cash condition to $35 million from $60 million. Additionally, the SPAC disclosed last month that it added a $17.8 million convertible share investment and a $2 million backstop to its combination with the drug developer.

Denver-based TriSalus is developing a range of cancer treatments that utilize the company’s approved and commercialized medical device. In April, TriSalus presented clinical data from its Phase I trials, which indicated positive results in reducing tumor growth in liver cancer patients.

The combined company is expected to trade on the Nasdaq under the symbol “TLSI” once the deal is completed.

 

 

Recent Posts
by Kristi Marvin on 2025-05-10 at 10:02am

Terms Tracker for the Week Ending May 9, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. After the sprint that was last week, with nine IPOs and six new SPAC filings, this week took a breather. Only two SPACs priced, there...

by Nicholas Alan Clayton on 2025-05-09 at 12:17pm

Lake Superior (NASDAQ:LKSPU) has filed for a $100 million SPAC as its CEO attempts to go three-for-three with SPACs that led to completed deals. This new vehicle has one right to a 1/6 share in each unit and some common features of a SPAC underwritten by Cohen & Company in this current climate. Although the...

by Nicholas Alan Clayton on 2025-05-09 at 8:20am

At the SPAC of Dawn De-SPACs were among the biggest movers in yesterday’s stock market rally, but most of this momentum came on the backs of direct earnings performance. Only three US-listed companies had bigger one-day gains than quantum computing firm D-Wave’s (NYSE:QBTS) +51.2% jump. This came as the company announced $15 million in revenue...

by Nicholas Alan Clayton on 2025-05-08 at 4:57pm

EGH Acquisition Corp. (NASDAQ:EGHAU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EGHAU”, Friday, May 8, 2025. The new SPAC aims to combine with a target company in the energy transition or sustainability arena that help industries achieve efficiencies and decarbonization....

by Nicholas Alan Clayton on 2025-05-08 at 8:25am

At the SPAC of Dawn Fed Chair Jerome Powell announced yesterday that the body intends to keep rates unchanged, earning him the moniker “FOOL” by US President Donald Trump. But, the announcement could bring some stability to market, which has seen macro factors pull it a variety of directions since the start of the year....

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved